Mark Holoboski
DuPont
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mark Holoboski.
Pharmaceutical patent analyst | 2004
Larry A. Wheeler; Michael E. Garst; Yanbin Liang; David F. Woodward; Achim H.-P. Krauss; Robert M. Burk; Yariv Donde; Mark Holoboski; David W. Old; June Chen
Prostaglandin antagonists, with their pharmacological effects, are well-known drugs capable of treating widely diffused illnesses, including pain and inflammation disorders. In recent years, a major research focus has been devoted to the identification of agents able to selectively antagonize each receptor with which prostaglandins interact. This review attempts to give a broad overview of molecules capable of selectively blocking the prostaglandin PGE2 EP4 receptor. Further therapeutic applications and uses have also been disccussed, including the first drug candidate to have reached clinical trials within the last few years.
Archive | 2002
Robert M. Burk; Mark Holoboski; Mari F. Posner
Archive | 2002
Robert M. Burk; Mark Holoboski; Mari F. Posner
Archive | 2005
Wha-Bin Im; Robert M. Burk; Mark Holoboski
Archive | 2003
David F. Woodward; Achim H.-P. Krauss; Robert M. Burk; Mark Holoboski; Mari F. Posner
Archive | 2009
Scott M. Whitcup; Robert M. Burk; David W. Old; Yariv Donde; Wha-Bin Im; Mark Holoboski
Archive | 2008
David W. Old; Mark Holoboski; Mari F. Posner
Archive | 2001
Robert M. Burk; Mark Holoboski; Mari F. Posner
Archive | 2007
Wha Bin Im; Robert M. Burk; Mark Holoboski
Archive | 2005
Robert M. Burk; Mark Holoboski; Scott M. Whitcup; Wha-Bin Im